ReviewChronic diseases and translational medicine2026
Efficacy and Safety of Durvalumab and Tremelimumab in Metastatic Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Review in Chronic diseases and translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Immune checkpoint inhibitors have transformed treatment strategies for metastatic non-small cell lung cancer (mNSCLC). This study aimed to assess the efficacy and safety of durvalumab combined with tremelimumab compared with those of standard chemotherapy, particularly in patients with low or negative PD-L1 expression, and in the overall population. Methods: A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted following PRISMA 2020 guidelines. Pooled efficacy and safety outcomes were calculated as hazard ratios (HRs) and risk ratios (RRs) with 95% confidence intervals (CIs). Results: Three RCTs ( Conclusions: Durvalumab plus tremelimumab may be a promising alternative to chemotherapy in patients with mNSCLC with low PD-L1 expression for improving OS, although the PFS and ORR benefits were not significant in the overall population. This combination has a favorable safety profile, although it is associated with a higher risk of serious TRAEs. Further studies are required to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.